Dendrimer |
Doxorubicin |
Polylysine dendrimer |
IV |
Increase of systemic exposure, accumulation in tumor cells |
Flurbiprofen |
Poly(amidoamine) dendrimer |
IV |
Increase of distribution and retentions in inflammatory sites |
Methotrexate |
PEGylated polylysine dendrimer |
IV |
Prolongation of systemic exposure |
Lactoferrin-conjugated dendrimer |
IV |
Accumulation in lungs |
Piroxicam |
Poly(amidoamine) dendrimer |
IV |
Prolongation of systemic exposure |
Engineered NPs |
Carbendazim |
Nanocrystals |
PO |
Increase of oral F |
Cilostazol |
Nanocrystals |
PO |
Increase of oral F |
Curcumin |
Nanocrystals |
PO |
Increase of oral F |
Danazol |
Nanocrystals |
PO |
Increase of oral F |
Diclofenac |
SoluMatrix™ fine particle |
PO |
Rapid absorption, pain relief |
Fenofibrate |
Nanocrystals |
PO |
Increase of oral F |
Indomethacin |
SoluMatrix fine particle |
PO |
Rapid absorption |
Megestrol acetate |
Nanocrystals |
PO |
Increase of oral F |
Nitrendipine |
Nanocrystals |
PO |
Increase of oral F |
Nobiletin |
Nanosized amorphous particles |
PO |
Increase of oral F, liver protective effect |
Tranilast |
Nanocrystals |
PO |
Increase of oral F, rapid absorption |
Inhalable nanocrystalline powders |
Lungs |
Increase of anti-inflammatory effect in lungs |
Paclitaxel |
Albumin nanoparticles |
IV |
Tumor targeting |
Lipid |
Emulsion |
Cinnarizine |
Self-emulsifying drug delivery |
PO |
Increase of oral F |
Coenzyme Q10 |
Solid self-emulsifying delivery |
PO |
Increase of oral F |
Cyclosporin A |
Self-emulsifying drug delivery |
PO |
Increase of oral F |
Inhalable dry emulsions |
Lungs |
Increase of anti-inflammatory effect in lungs |
Halofantrine |
Self-emulsifying drug delivery |
PO |
Increase of oral F |
Simvastatin |
Self-emulsifying drug delivery |
PO |
Increase of oral F |
Liposomes |
Amikacin |
Liposome (Phospholipid/Chol) |
IV |
Increase of half-life |
Amphotericin B |
Liposome (PC/Chol/DSPG) |
IV |
Increase of systemic exposure, decrease of RES uptake |
Cytarabine/daunorubicin |
Liposome (DSPC/DSPG/Chol) |
IV |
CL reduction |
Doxorubicin |
Liposome, PEGylated liposome |
IV |
Increase of distribution in tumor cells |
O-palmitoyl tilisolol |
Liposome (PC/Chol) |
IV |
Increase of distribution |
Paclitaxel |
Liposome (PC/PG) |
IV |
Prolongation of systemic exposure |
Prednisolone |
Liposome (PC/Chol/10% DSPE-PEG2000) |
IV |
Prolongation and increase of systemic exposure |
Solid lipid NPs |
Azidothymidine |
Solid lipid NPs |
IV |
Increase of permeability and retention time in brain |
Clozapine |
Solid lipid NPs |
IV |
Increase of systemic exposure, CL reduction |
Diclofenac Na |
Solid-in-oil NPs |
Skin |
Increase of percutaneous absorption |
Insulin |
Lectin-modified solid lipid NPs |
PO |
Increase of oral F |
Lidocaine |
Solid lipid nanoparticles |
Skin |
Regulation of skin permeability |
Micelles |
Camptothecin |
Block copolymeric micelles |
IV |
Increase of systemic exposure |
Doxorubicin |
Block copolymeric micelles |
IV |
Increase of systemic exposure, CL reduction |
Paclitaxel |
Block copolymeric micelles |
IV |
Increase of systemic exposure, CL reduction |
Pilocarpine |
Block copolymeric micelles |
Eyes |
Increase of efficacy |
Tranilast |
Self-micellizing solid dispersion |
PO |
Increase of oral F |
Polymeric NPs |
Celecoxib |
Ethyl cellulose/casein NPs |
PO |
Increase of oral F |
Clotrimazole/econazole |
PLGA and alginate NPs |
PO |
Increase of oral F |
Docetaxel |
PLA-PEG NPs |
IV |
Increase of half-life and anti-cancer effect |
Doxorubicin |
PLGA NPs |
IV, IP |
Increase of half-life, decrease of distribution in heart |
Glucagon |
PLGA NPs |
Lungs |
Increase of half-life, increase of oral F |
Glucagon |
PLGA NPs |
Lungs |
Increase of oral F and half-life |
Insulin |
Hydrogel NPs |
PO |
Increase of oral F |
Rifampicin |
PLGA NPs |
PO |
Increase of oral F |
siRNA |
Chitosan analog NPs |
PO |
Increase of systemic exposure, gene silencing |
VIP derivative |
PLGA NPs |
Lungs |
Anti-inflammatory effect |